In order to provide you with a better browsing experience and to improve our site functionality, we use cookies and other tracking technologies. Detailed information on the use of cookies on our site and how to opt out is provided in our Cookie Policy. By clicking into any content on this site, you consent that we can store and access cookies and other tracking technologies as described in our Cookie Policy.

News Release

October 3, 2022

Fujifilm to establish a local subsidiary in South Korea to accelerate business growth of cell culture media

Boosting support for customers through direct sales and marketing

TOKYO, October 3, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces the establishment of a local subsidiary in South Korea to accelerate business growth of cell culture media. The new subsidiary will commence its business operations on October 4. It will offer high-quality cell culture media for bioproduction and advanced cell and gene therapies. It will be able to, through direct sales and marketing, provide custom media which fulfill local customers’ needs.

The market for cell culture media is currently expanding at the rate of more than 10%*1 along with the increasing demand for antibody drugs and vaccines as well as the development of advanced cell and gene therapies. In particular, the market in South Korea is growing at the rate of approximately 15%*1 and is expected to continue its growth in the future.

Fujifilm is currently expanding the business of cell culture media with its subsidiaries FUJIFILM Wako Pure Chemical and FUJIFILM Irvine Scientific, Inc., providing high quality and functional products by leveraging its global sales networks, R&D and quality assurance capabilities and cGMP manufacturing facilities in Japan, the United States and Europe.

“The establishment of a new subsidiary is an important step toward further business expansion in the rapidly-growing market in South Korea” said Yutaka Yamaguchi, corporate vice president, general manager of Life Sciences Business Division, FUJIFILM Corporation. “Fujifilm will, as a partner for customers in the bio industry, continue to strongly support their research, development and manufacturing, thereby contributing to the further progress in medicine that leads to people’s health.”

  • *1 As of October 3, 2022 according to Fujifilm.

Overview of the new local subsidiary

Company Name

FUJIFILM Life Sciences Korea Co., Ltd.


Seoul Special City, South Korea

Paid-in Capital

300 million KRW


Jun Muto

Business Description

Import, sales and marketing of cell culture media for bioproduction and advanced cell and gene therapies


Media Contact

FUJIFILM Holdings Corporation
Corporate Communications Division,
Public Relations Group

Other Inquiries

Life Sciences Business Division

  • * Please note that the contents in this website are current as of the date of the press announcement and may be subject to change without prior notice. Information in each release, including the product availability, specification, prices, contacts, are those at the time of publication.